Page last updated: 2024-10-19

niacin and Diabetes Mellitus, Adult-Onset

niacin has been researched along with Diabetes Mellitus, Adult-Onset in 102 studies

Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.

Research Excerpts

ExcerptRelevanceReference
"The aim of this study was to evaluate the effects of low-dose niacin extended-release (niacin-ER) combined with simvastatin (SV) in the treatment of patients with mixed dyslipidemia who have not normalized their lipid profile with statin therapy alone."9.14Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad. ( Casulari, LA; Dos Santos, AM; Salgado, BJ; Salgado, JV, 2010)
"To assess the efficacy and safety of ezetimibe/simvastatin (E/S) plus extended-release niacin (N) in hyperlipidaemic patients with diabetes mellitus (DM), metabolic syndrome (MetS) without DM (MetS/non-DM) or neither (non-DM/non-MetS)."9.14Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. ( Fazio, S; Guyton, JR; Lin, J; Shah, A; Tershakovec, AM; Tomassini, JE, 2010)
"We assumed that adding the niacin to the medication in patients with type 2 diabetes would reduce dyslipidemia and achieve target lipid levels."5.41The efficacy of niacin supplementation in type 2 diabetes patients: Study protocol of a randomized controlled trial. ( Wang, S; Yan, X, 2021)
"The aim of this study was to evaluate the effects of low-dose niacin extended-release (niacin-ER) combined with simvastatin (SV) in the treatment of patients with mixed dyslipidemia who have not normalized their lipid profile with statin therapy alone."5.14Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad. ( Casulari, LA; Dos Santos, AM; Salgado, BJ; Salgado, JV, 2010)
"To assess the efficacy and safety of ezetimibe/simvastatin (E/S) plus extended-release niacin (N) in hyperlipidaemic patients with diabetes mellitus (DM), metabolic syndrome (MetS) without DM (MetS/non-DM) or neither (non-DM/non-MetS)."5.14Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. ( Fazio, S; Guyton, JR; Lin, J; Shah, A; Tershakovec, AM; Tomassini, JE, 2010)
"To investigate the effect of low-dose aspirin administered in the morning or evening on the rate of discontinuation of prolonged-release nicotinic acid (Niaspan) due to flushing in patients at elevated cardiovascular risk."5.13Influence of the timing of low-dose aspirin on tolerability of prolonged-release nicotinic acid in patients at elevated cardiovascular risk. ( Alves, JD; Darioli, R; Hostalek, U; Steinhagen-Thiessen, E; Vogt, A, 2008)
"Low-dose niacin is a promising addition to hydroxymethylglutaryl-coenzyme A reductase inhibitor therapy in the treatment of hypercholesterolemia in patients with diabetes mellitus."5.08Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control. ( Fonseca, VA; Gardner, SF; Granberry, MC; Marx, MA; Skelton, DR; White, LM, 1997)
"The prevalences of diabetes and adult obesity were highly correlated with per capita consumption of niacin, thiamin and riboflavin with a 26-and 10-year lag, respectively (R2 = 0."3.76B-vitamin consumption and the prevalence of diabetes and obesity among the US adults: population based ecological study. ( Li, D; Liu, QG; Sun, WP; Zhou, SS; Zhou, YM, 2010)
"Fenofibrate was a cost-effective either as monotherapy or combined with a statin compared to statin or fenofibrate monotherapy."3.01A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus. ( Abushanab, D; Ademi, Z; Al-Badriyeh, D; Bailey, C; Jaam, M; Liew, D; Marquina, C, 2023)
"In statin-treated men with type 2 diabetes mellitus, ERN decreased plasma Lp(a) concentrations by decreasing the production of apo(a) and Lp(a)-apoB-100."2.80Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus. ( Barrett, PH; Chan, DC; Hamilton, SJ; Marcovina, SM; McCormick, SP; Ooi, EM; Pang, J; Tenneti, VS; Watts, GF, 2015)
"Twelve men with type 2 diabetes mellitus were recruited for a randomized, crossover design trial."2.79Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus. ( Barrett, PH; Chan, DC; Hamilton, SJ; Pang, J; Tenneti, VS; Watts, GF, 2014)
"placebo on the incidence of new onset type 2 diabetes mellitus (T2DM) and cardiovascular event rates in patients with normal and impaired fasting glucose (IFG)."2.78Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose. ( Canner, PL; Maccubbin, D; Sazonov, V; Sisk, CM, 2013)
"HDL from patients with type 2 diabetes mellitus and metabolic syndrome has substantially impaired endothelial-protective effects compared with HDL from healthy subjects."2.75Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. ( Bahlmann, FH; Bahr, MJ; Besler, C; Doerries, C; Drexler, H; Flemmer, S; Haller, H; Heinemann, M; Heinrich, K; Horváth, T; Landmesser, U; Manes, C; Markowski, A; Meyer, M; Mueller, M; Rohrer, L; Sorrentino, SA; von Eckardstein, A, 2010)
"Diabetic dyslipidemia is characterized by high triglyceride levels; low high-density lipoprotein cholesterol levels; small, dense low-density lipoprotein particles; and high free fatty acid levels."2.70Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. ( Buse, JB; Fitz-Patrick, D; Ganda, OP; Grundy, SM; Kendall, DM; McGovern, ME; Robertson, DD; Rosenson, RS; Sheehan, JP; Tulloch, BR; Vega, GL, 2002)
" Our analysis also showed the absence of publication bias and any dose-response relations between niacin and effect size."2.52Effect of niacin on lipids and glucose in patients with type 2 diabetes: A meta-analysis of randomized, controlled clinical trials. ( Ding, Y; Li, Y; Wen, A, 2015)
"In the metabolic syndrome and type 2 diabetes, excess energy intake on the background of genetic predisposition and lifestyle factors leads to the dysregulation of fatty acid metabolism and acquired insulin resistance."2.48Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes. ( Matikainen, N; Taskinen, MR, 2012)
"Low HDL-C levels are common in type 2 diabetes but are not currently recommended as a target for treatment because of the lack of definitive cardiovascular outcome studies supporting this goal, and because of the difficulty in raising HDL-C."2.46Management of dyslipidemia in people with type 2 diabetes mellitus. ( Dunn, FL, 2010)
"It is generally accepted that type 2 diabetes is the result of gene-environmental interaction."2.46[Chronic nicotinamide overload and type 2 diabetes]. ( Li, D; Liu, XX; Lun, YZ; Sun, WP; Zhou, SS; Zhou, YM, 2010)
"The lipid profile of type 2 diabetes mellitus is characterized by increased triglycerides (TGs), decreased high-density lipoprotein cholesterol (HDL-C), increased very low density lipoproteins (VLDLs), and small, dense low-density lipoprotein particles, the combination of which is highly atherogenic."2.45Managing diabetic dyslipidemia: beyond statin therapy. ( Gadi, R; Neeli, H; Rader, DJ, 2009)
"Patients with type 2 diabetes have a marked increase in the risk of premature coronary heart disease (CHD)."2.44Dyslipidaemia in diabetic patients: time for a rethink. ( Shepherd, J, 2007)
"Both diabetes and metabolic syndrome are associated with a clustering of cardiovascular risk factors."2.43Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. ( Betteridge, J; Shepherd, J; Van Gaal, L, 2005)
"The metabolic syndrome and type 2 diabetes mellitus are both becoming more prevalent, and both increase the risk of cardiovascular disease."2.43Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. ( Nesto, RW, 2005)
"Dyslipidemia is characterized by increased triglyceride-rich lipoproteins; low high-density lipoprotein cholesterol; small, dense low-density lipoprotein particles; increased postprandial lipemia; and abnormal apolipoprotein A1 and B metabolism."2.42Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. ( Cottrell, DA; Falko, JM; Marshall, BJ, 2003)
"Treatment of the dyslipidemia associated with type 2 diabetes and FCHL with a combination of a statin and a thiazolidinedione or niacin offers the most comprehensive modality to correct the various lipid abnormalities."2.42Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. ( Ayyobi, AF; Brunzell, JD, 2003)
"Patients with NIDDM are unable to increase their glucose oxidation normally in response to insulin to meet the energy demands of the body."2.38Insulin action and substrate competition. ( Ferrannini, E; Groop, LC, 1993)
"Prediabetes is a metabolic condition associated with gut microbiome composition, although mechanisms remain elusive."1.91A Fecal Metabolite Signature of Impaired Fasting Glucose: Results From Two Independent Population-Based Cohorts. ( Asnicar, F; Bagnardi, V; Baleanu, AF; Bell, JT; Breuninger, T; Christiansen, C; Dong, Q; Falchi, M; Franks, PW; Gieger, C; Grallert, H; Linseisen, J; Louca, P; Menni, C; Michelotti, GA; Nogal, A; Peters, A; Segata, N; Spector, TD; Tettamanzi, F; Valdes, AM; Visconti, A; Wawro, N; Wong, K, 2023)
"60 patients with DPN and type 2 diabetes mellitus with a disease duration of 6 to 25 years were examined and treated."1.56[The effect of complex use of nicotinic acid electrophoresis and air bubble baths on microcirculation in patients with diabetic polyneuropathy]. ( Kolbakhova, SN; Konchugova, TV; Kulchitskaya, DB; Tsoi, AV; Turova, EA, 2020)
"Niacin is a popular nutritional supplement known to reduce the risk of cardiovascular diseases by enhancing high-density lipoprotein levels."1.42Involvement of the Niacin Receptor GPR109a in the LocalControl of Glucose Uptake in Small Intestine of Type 2Diabetic Mice. ( Chan, LK; Leung, PS; Wong, TP, 2015)
"Patients with type 2 diabetes and hyperlipidemia were included for review if they received the combination of pioglitazone at doses ≥ 15 mg/day and extended-release niacin (Niaspan) at doses ≥ 1000 mg/day for ≥6 months."1.39The effect of pioglitazone and extended-release niacin on HDL-cholesterol in diabetes patients in a real-world setting. ( Bhargava, A; Gleason, S; Johnson, JF; Vaughan, AG; Yarlagadda, KV, 2013)
"Patients with type 2 diabetes have increased expression of cell adhesion molecules (CAMs)."1.37Niacin results in reduced monocyte adhesion in patients with type 2 diabetes mellitus. ( Dong, X; Jauhar, N; Lim, SC; Pek, LT; Sum, CF; Tavintharan, S; Woon, K, 2011)
"In subjects with prevalent type 2 diabetes, homozygous carriers of the most common SIRT1 haplotype, 1, had 1."1.35SIRT1 genetic variation and mortality in type 2 diabetes: interaction with smoking and dietary niacin. ( Dehghan, A; Hofman, A; Pols, HA; Rivadeneira, F; Sijbrands, EJ; Uitterlinden, AG; van Duijn, CM; van Leeuwen, JP; van Meurs, JB; Witteman, JC; Zillikens, MC, 2009)
"Niacin has recently been shown to increase serum total concentrations of the adipocyte-derived protein adiponectin."1.35Increased total and high-molecular weight adiponectin after extended-release niacin. ( Brunson, BL; Grandjean, PW; Judd, RL; Plaisance, EP, 2008)
" The primary endpoint was the safety and tolerability of prolonged-release nicotinic acid, with special regard to treatment-related adverse drug reactions (ADRs)."1.34Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients. ( Assmann, G; Birjmohun, RS; Hostalek, U; Kastelein, JJ; Poldermans, D; Stroes, ES, 2007)
"Ten patients with NIDDM, CAD, and severe LV dysfunction (mean ejection fraction, 29."1.31Myocardial glucose utilization and optimization of (18)F-FDG PET imaging in patients with non-insulin-dependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction. ( Beanlands, RS; deKemp, RA; Ruddy, TD; Vitale, GD; Williams, K, 2001)
"Patients received Niaspan 1000, 1500, or 2000 mg/day (median daily dosage 1000 mg)."1.31Cholesterol and glycemic effects of Niaspan in patients with type 2 diabetes. ( Addesse, E; Bakst, G; Busch, RS; Hamilton, RA; Kane, MP, 2001)
"Glycerol, which was present in the infused lipid (272 mmol/l) did not affect ISR."1.30Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes. ( Boden, G; Chen, X, 1999)

Research

Studies (102)

TimeframeStudies, this research(%)All Research%
pre-19902 (1.96)18.7374
1990's12 (11.76)18.2507
2000's41 (40.20)29.6817
2010's40 (39.22)24.3611
2020's7 (6.86)2.80

Authors

AuthorsStudies
Abushanab, D1
Al-Badriyeh, D1
Marquina, C1
Bailey, C1
Jaam, M1
Liew, D1
Ademi, Z1
Xia, J1
Yu, J1
Xu, H1
Zhou, Y1
Li, H1
Yin, S1
Xu, D1
Wang, Y1
Xia, H1
Liao, W1
Wang, S2
Sun, G1
Nogal, A1
Tettamanzi, F1
Dong, Q2
Louca, P1
Visconti, A1
Christiansen, C1
Breuninger, T1
Linseisen, J1
Grallert, H1
Wawro, N1
Asnicar, F1
Wong, K1
Baleanu, AF1
Michelotti, GA1
Segata, N1
Falchi, M1
Peters, A1
Franks, PW1
Bagnardi, V1
Spector, TD1
Bell, JT1
Gieger, C1
Valdes, AM1
Menni, C1
Massimino, E1
Izzo, A1
Castaldo, C1
Amoroso, AP1
Rivellese, AA1
Capaldo, B1
Della Pepa, G1
Kulchitskaya, DB1
Turova, EA1
Konchugova, TV1
Kolbakhova, SN1
Tsoi, AV1
Xiang, D1
Zhang, Q1
Wang, YT1
Yan, X1
Skolnik, N1
Jaffa, FM1
Kalyani, RR1
Johnson, E1
Shubrook, JH1
Fangmann, D1
Theismann, EM1
Türk, K1
Schulte, DM1
Relling, I1
Hartmann, K1
Keppler, JK1
Knipp, JR1
Rehman, A1
Heinsen, FA1
Franke, A1
Lenk, L1
Freitag-Wolf, S1
Appel, E1
Gorb, S1
Brenner, C1
Seegert, D1
Waetzig, GH1
Rosenstiel, P1
Schreiber, S1
Schwarz, K1
Laudes, M1
Xie, YD1
Chen, ZZ1
Li, N1
Lu, WF1
Xu, YH1
Lin, YY1
Shao, LH1
Wang, QT1
Guo, LY1
Gao, YQ1
Yang, GD1
Li, YP1
Bian, XL1
Wierzbicki, AS1
Sazonov, V2
Maccubbin, D4
Sisk, CM3
Canner, PL1
Reiner, Z1
Christou, GA1
Rizos, EC1
Mpechlioulis, A1
Penzo, C1
Pacchioni, A1
Nikas, DN1
Bhargava, A1
Gleason, S1
Vaughan, AG1
Johnson, JF1
Yarlagadda, KV1
Stevens, BD1
Litchfield, J1
Pfefferkorn, JA1
Atkinson, K1
Perreault, C1
Amor, P1
Bahnck, K1
Berliner, MA1
Calloway, J1
Carlo, A1
Derksen, DR1
Filipski, KJ1
Gumkowski, M1
Jassal, C1
MacDougall, M1
Murphy, B1
Nkansah, P1
Pettersen, J1
Rotter, C1
Zhang, Y1
Pang, J3
Chan, DC3
Hamilton, SJ4
Tenneti, VS3
Watts, GF4
Barrett, PH3
Manoria, PC1
Chopra, HK1
Parashar, SK1
Dutta, AL1
Pinto, B1
Mullasari, A1
Prajapati, S1
Hafiane, A1
Kellett, S1
Genest, J1
Ding, Y1
Li, Y1
Wen, A1
Masana, L2
Cabré, A1
Heras, M2
Amigó, N2
Correig, X2
Martínez-Hervás, S2
Real, JT1
Ascaso, JF1
Quesada, H1
Julve, J1
Palomer, X1
Vázquez-Carrera, M1
Girona, J1
Plana, N2
Blanco-Vaca, F1
Bays, HE2
Brinton, EA2
Triscari, J2
Chen, E2
MacLean, AA2
Gibson, KL1
Ruck, RA2
Johnson-Levonas, AO2
O'Neill, EA2
Mitchel, YB2
Wong, TP1
Chan, LK1
Leung, PS1
Ooi, EM1
McCormick, SP1
Marcovina, SM1
Misra, A1
Bhardwaj, S1
Mallol, R1
Blanco Vaca, F1
Escolà-Gil, JC1
Yanes, Ó1
Brudi, P1
Collins, PD1
Sattar, N1
Nichols, GA1
Reynolds, K1
Olufade, T1
Kimes, TM1
O'Keeffe-Rosetti, M1
Sapp, DS1
Anzalone, D1
Fortmann, SP1
Alves, JD1
Steinhagen-Thiessen, E1
Darioli, R1
Hostalek, U2
Vogt, A1
Davidson, M1
Jones, PH1
McNamara, DB1
Murthy, SN1
Fonseca, AN1
Desouza, CV1
Kadowitz, PJ1
Fonseca, VA2
Zillikens, MC1
van Meurs, JB1
Sijbrands, EJ1
Rivadeneira, F1
Dehghan, A1
van Leeuwen, JP1
Hofman, A1
van Duijn, CM1
Witteman, JC1
Uitterlinden, AG1
Pols, HA1
Tan, KC1
Neeli, H1
Gadi, R1
Rader, DJ1
Merkel, M1
Ginsberg, HN1
Maccallum, PR1
Bitzur, R1
Cohen, H1
Kamari, Y1
Shaish, A1
Harats, D1
Libby, A1
Meier, J1
Lopez, J1
Swislocki, AL1
Siegel, D1
Sorrentino, SA1
Besler, C1
Rohrer, L1
Meyer, M1
Heinrich, K1
Bahlmann, FH1
Mueller, M1
Horváth, T1
Doerries, C1
Heinemann, M1
Flemmer, S1
Markowski, A1
Manes, C1
Bahr, MJ1
Haller, H1
von Eckardstein, A1
Drexler, H1
Landmesser, U1
Zhou, SS2
Li, D2
Zhou, YM2
Sun, WP2
Liu, XX1
Lun, YZ1
Dunn, FL1
Pan, J1
Shilian, P1
Ishida, B1
Wu, X1
Kane, JP1
Malloy, MJ1
Charles, MA1
Yoshinari, O1
Igarashi, K1
Jialal, I1
Amess, W1
Kaur, M1
Chew, GT1
Davis, TM1
Wallach, I1
Jaitly, N1
Lilien, R1
Fazio, S1
Guyton, JR1
Lin, J2
Tomassini, JE1
Shah, A2
Tershakovec, AM2
Salgado, BJ1
Salgado, JV1
Dos Santos, AM1
Casulari, LA1
Liu, QG1
Ambegaonkar, BM1
Wentworth, C1
Allen, C1
Tavintharan, S1
Woon, K1
Pek, LT1
Jauhar, N1
Dong, X1
Lim, SC1
Sum, CF1
Bays, H1
Giezek, H1
McKenney, JM1
Matikainen, N1
Taskinen, MR1
Grundy, SM2
Vega, GL1
McGovern, ME1
Tulloch, BR1
Kendall, DM1
Fitz-Patrick, D1
Ganda, OP1
Rosenson, RS2
Buse, JB1
Robertson, DD1
Sheehan, JP1
Tomono, S1
Ohyama, Y1
Uchiyama, T1
Packard, C1
Olsson, AG1
Mikhail, N1
Cottrell, DA1
Marshall, BJ1
Falko, JM2
Ayyobi, AF1
Brunzell, JD1
Hawkins, M2
Tonelli, J2
Kishore, P2
Stein, D1
Ragucci, E1
Gitig, A1
Reddy, K2
Wild, S1
Byrne, CD1
Meyers, CD1
Kamanna, VS1
Kashyap, ML1
Rassman, J1
Gupta, S1
März, W1
Shepherd, J2
Betteridge, J1
Van Gaal, L1
Carpentier, AC1
Frisch, F1
Cyr, D1
Généreux, P1
Patterson, BW1
Giguère, R1
Baillargeon, JP1
Rasouli, N1
Hale, T1
Kahn, SE2
Spencer, HJ1
Elbein, SC1
Nesto, RW1
Koppaka, S1
Fratila, C1
Bose, A1
Lee, DE1
Rink, C1
Roy, S1
Khanna, S1
Rink, T1
Bagchi, D1
Sen, CK1
Tenenbaum, A1
Fisman, EZ1
Motro, M1
Adler, Y1
Tahrani, AA1
Rana, JS1
Nieuwdorp, M1
Jukema, JW1
Kastelein, JJ2
Birjmohun, RS1
Poldermans, D1
Stroes, ES1
Assmann, G1
Moser, RJ1
Meis, SB1
Caulin-Glaser, T1
Plaisance, EP1
Grandjean, PW1
Brunson, BL1
Judd, RL1
Cannon, CP1
Tsalamandris, C1
Panagiotopoulos, S1
Sinha, A1
Cooper, ME1
Jerums, G1
Groop, LC1
Ferrannini, E1
Saloranta, C1
Groop, L1
Thomas, VL1
Gropper, SS1
Gardner, SF1
Marx, MA1
White, LM1
Granberry, MC1
Skelton, DR1
Boden, G2
Chen, X2
Iqbal, N1
Gotto, AM1
Worm, D1
Vinten, J1
Vaag, A1
Henriksen, JE1
Beck-Nielsen, H1
Vitale, GD1
deKemp, RA1
Ruddy, TD1
Williams, K1
Beanlands, RS1
Kane, MP1
Hamilton, RA1
Addesse, E1
Busch, RS1
Bakst, G1
Foley, JE1
Johnston, P1
Hollenbeck, C1
Sheu, W1
Chen, YD1
Reaven, GM1
Garg, A1
Porte, D1
Berova, N1
Lazarova, A1

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicenter, Randomized, Double-Blind, Placebo Controlled 36 Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients With Type 2 Diabetes[NCT00485758]Phase 3796 participants (Actual)Interventional2007-07-31Completed
Post-prandial Effects of Extra Virgin Olive Oil on Endothelial Function in Adults at Risk for Type 2 Diabetes: A Randomized Crossover Controlled Trial[NCT04025281]20 participants (Actual)Interventional2019-07-09Completed
The Impact of Consumption of Eggs in the Context of Plant-Based Diets on[NCT04316429]35 participants (Actual)Interventional2020-06-09Completed
Randomized Clinical Trial to Study the Effect of Extended Release Niacin on Endothelial Function, Oxidative Stress and Endothelial Progenitor Cells in Patients With the Metabolic Syndrome.[NCT00346970]Phase 432 participants (Actual)Interventional2006-07-31Completed
"A Multicenter, Randomized, Double-Blind, Factorial Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Coadministered MK0524B Tablets in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia"[NCT00269217]Phase 31,400 participants (Actual)Interventional2006-01-31Completed
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia[NCT00269204]Phase 31,620 participants (Actual)Interventional2005-12-31Completed
A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of Extended-release (ER) Niacin/Laropiprant in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia.[NCT00479388]Phase 31,216 participants (Actual)Interventional2007-07-31Completed
Randomized, Double-blind, Placebo-controlled Trial of Niaspan® in Patients With Overt Diabetic Nephropathy and Moderate Renal Impairment[NCT00108485]Phase 39 participants (Actual)Interventional2005-04-30Terminated (stopped due to Unable to recruit sufficient study subjects)
Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol[NCT01131299]Phase 2103 participants (Actual)Interventional2010-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in High Density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo

After 12 weeks of treatment, to assess the increase of high-density lipoprotein cholesterol in patients with Type 2 diabetes when compared to placebo (NCT00485758)
Timeframe: Baseline and 12 Weeks

InterventionPercent change at Wk 12 compared to Bl (Least Squares Mean)
Extended Release Niacin/Laropiprant25.4
Placebo2.2

Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo

After 12 Weeks of treatment, to assess the reduction of low-density lipoprotein cholesterol in patients with Type 2 diabetes when compared to placebo (NCT00485758)
Timeframe: Baseline and 12 Weeks

InterventionPercent change at Wk 12 compared to Bl (Least Squares Mean)
Extended Release Niacin/Laropiprant-15.8
Placebo2.1

Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Triglycerides in Patients With Type 2 Diabetes When Compared to Placebo

after 12 weeks of treatment, to assess the reduction of triglycerides in patients with Type 2 diabetes when compared to placebo (NCT00485758)
Timeframe: Baseline and 12 Weeks

InterventionPercent change at Wk 12 compared to Bl (Median)
Extended Release Niacin/Laropiprant-22.2
Placebo2.3

Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12

(NCT00479388)
Timeframe: Baseline and 12 Weeks

InterventionPercent (Least Squares Mean)
ER Niacin/Laropiprant + Run-in Statin15.8
Run-in Statin Dose Doubled0.2

Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12

(NCT00479388)
Timeframe: Baseline and 12 Weeks

InterventionPercent (Least Squares Mean)
ER Niacin/Laropiprant + Run-in Statin-10.0
Run-in Statin Dose Doubled-5.5

Percent Change From Baseline in Triglycerides at Week 12

(NCT00479388)
Timeframe: Baseline and 12 Weeks

InterventionPercent (Median)
ER Niacin/Laropiprant + Run-in Statin-17.6
Run-in Statin Dose Doubled-4.0

Change in Proteinuria

(NCT00108485)
Timeframe: Baseline, 1 year

Interventionmg/dL (Number)
Extended Release Niacin42
Placebo63

Lipoprotein Insulin Resistance Index (LIRI) After 12-14 Weeks Intervention, Compared to Baseline for Alpha-cyclodextrin (a-CD) and Placebo Groups After 12-14 Weeks, Compared to Baseline

LIRI was measured at the end of each study arm (a-CD or placebo). a-CD (2g) was taken orally three times a day for 12-14 weeks. Placebo (2 tablets) was taken orally for 12-14 weeks. There was a one-week washout period between each arm. (NCT01131299)
Timeframe: 24-28 weeks

Interventionpercentage (Mean)
a-CD1.4
Placebo1.6

Serum Glucose Levels After 12-14 Weeks Intervention, Compared to Baseline for Alpha-cyclodextrin (a-CD) and Placebo Groups After 12-14 Weeks, Compared to Baseline

Serum glucose levels was measured at the end of each study arm (a-CD or placebo). a-CD (2g) was taken orally three times a day for 12-14 weeks. Placebo (2 tablets) was taken orally for 12-14 weeks. There was a one-week washout period between each arm. (NCT01131299)
Timeframe: 24-28 weeks

Interventionmg/dL (Mean)
a-CD87
Placebo88

Small LDL Particle Number (by NMR Spectrometry of Lipoproteins) After 12-14 Weeks Intervention, Compared to Baseline for Alpha-cyclodextrin (a-CD) and Placebo Groups After 12-14 Weeks, Compared to Baseline

Small LDL particle numbers were measured at the end of each study arm (a-CD or placebo). a-CD (2g) was taken orally three times a day for 12-14 weeks. Placebo (2 tablets) was taken orally for 12-14 weeks. There was a one-week washout period between each arm. (NCT01131299)
Timeframe: 24-28 weeks

Interventionnmol/L (Mean)
a-CD365
Placebo405

Total Serum Cholesterol Levels for Alpha-cyclodextrin (a-CD) and Placebo Groups After 12-14 Weeks, Compared to Baseline

Total cholesterol levels were measured at the end of each study arm (a-CD or placebo). a-CD (2g) was taken orally three times a day for 12-14 weeks. Placebo (2 tablets) was taken orally for 12-14 weeks. There was a one-week washout period between each arm. (NCT01131299)
Timeframe: 24-28 weeks

Interventionmg/dL (Mean)
a-CD180
Placebo180

Reviews

39 reviews available for niacin and Diabetes Mellitus, Adult-Onset

ArticleYear
A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus.
    Current problems in cardiology, 2023, Volume: 48, Issue:8

    Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2;

2023
Comparative effects of vitamin and mineral supplements in the management of type 2 diabetes in primary care: A systematic review and network meta-analysis of randomized controlled trials.
    Pharmacological research, 2023, Volume: 188

    Topics: Cholesterol; Chromium; Diabetes Mellitus, Type 2; Dietary Supplements; Humans; Micronutrients; Miner

2023
Effectiveness of niacin supplementation for patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Medicine, 2020, Jul-17, Volume: 99, Issue:29

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dietary Supplements; Humans; Lipids; Niacin; Randomized Co

2020
Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2013, Volume: 23, Issue:9

    Topics: Antibodies, Monoclonal; Anticholesteremic Agents; Apolipoprotein A-I; Benzimidazoles; Cardiovascular

2013
Confronting the residual cardiovascular risk beyond statins: the role of fibrates, omega-3 fatty acids, or niacin, in diabetic patients.
    Current pharmaceutical design, 2014, Volume: 20, Issue:22

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fatty Acids, Omega-3; Fibric Acids; Humans; Niac

2014
The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.
    Indian heart journal, 2013, Volume: 65, Issue:6

    Topics: Atherosclerosis; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Management;

2013
Treatment options for low high-density lipoproteins.
    Current opinion in endocrinology, diabetes, and obesity, 2014, Volume: 21, Issue:2

    Topics: Atherosclerosis; Biomarkers; Cholesterol Ester Transfer Proteins; Diabetes Mellitus, Type 2; Diabeti

2014
Effect of niacin on lipids and glucose in patients with type 2 diabetes: A meta-analysis of randomized, controlled clinical trials.
    Clinical nutrition (Edinburgh, Scotland), 2015, Volume: 34, Issue:5

    Topics: Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Databases, Factual; Diabetes Mellitus, Type 2; Fa

2015
Glycaemic Effects of Non-statin Lipid-Lowering Therapies.
    Current cardiology reports, 2016, Volume: 18, Issue:12

    Topics: Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabeti

2016
A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
    The American journal of cardiology, 2008, Dec-22, Volume: 102, Issue:12A

    Topics: Anticholesteremic Agents; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type 2; Drug Therapy,

2008
Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    The American journal of cardiology, 2008, Dec-22, Volume: 102, Issue:12A

    Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug

2008
Animal models of catheter-induced intimal hyperplasia in type 1 and type 2 diabetes and the effects of pharmacologic intervention.
    Canadian journal of physiology and pharmacology, 2009, Volume: 87, Issue:1

    Topics: Animals; Biguanides; Catheterization; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Di

2009
Reverse cholesterol transport in type 2 diabetes mellitus.
    Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:6

    Topics: Animals; Anticholesteremic Agents; Apolipoprotein A-I; ATP-Binding Cassette Transporters; Biological

2009
Managing diabetic dyslipidemia: beyond statin therapy.
    Current diabetes reports, 2009, Volume: 9, Issue:1

    Topics: Cholesterol, HDL; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Angi

2009
[Diabetic dyslipoproteinemia: beyond LDL].
    Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134, Issue:20

    Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Chy

2009
The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.
    Journal of clinical hypertension (Greenwich, Conn.), 2009, Volume: 11, Issue:9

    Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dysli

2009
Triglycerides and HDL cholesterol: stars or second leads in diabetes?
    Diabetes care, 2009, Volume: 32 Suppl 2

    Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Complications

2009
Triglycerides and HDL cholesterol: stars or second leads in diabetes?
    Diabetes care, 2009, Volume: 32 Suppl 2

    Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Complications

2009
Triglycerides and HDL cholesterol: stars or second leads in diabetes?
    Diabetes care, 2009, Volume: 32 Suppl 2

    Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Complications

2009
Triglycerides and HDL cholesterol: stars or second leads in diabetes?
    Diabetes care, 2009, Volume: 32 Suppl 2

    Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Complications

2009
[Chronic nicotinamide overload and type 2 diabetes].
    Sheng li xue bao : [Acta physiologica Sinica], 2010, Feb-25, Volume: 62, Issue:1

    Topics: Diabetes Mellitus, Type 2; Diet; Food, Fortified; Humans; Niacin; Niacinamide

2010
Management of dyslipidemia in people with type 2 diabetes mellitus.
    Reviews in endocrine & metabolic disorders, 2010, Volume: 11, Issue:1

    Topics: Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Ez

2010
Management of hypertriglyceridemia in the diabetic patient.
    Current diabetes reports, 2010, Volume: 10, Issue:4

    Topics: Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; H

2010
Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.
    Current cardiology reports, 2012, Volume: 14, Issue:6

    Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Fibric Acids;

2012
[Insulin resistance induced by drugs, inflammation and stress].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 7

    Topics: Adrenergic beta-Antagonists; Benzothiadiazines; Contraceptives, Oral, Hormonal; Cyclosporins; Diabet

2002
Management of hypercholesterolaemia in the patient with diabetes.
    International journal of clinical practice. Supplement, 2002, Issue:130

    Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, T

2002
Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.
    Current opinion in cardiology, 2003, Volume: 18, Issue:4

    Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopat

2003
Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia.
    The American journal of cardiology, 2003, Aug-18, Volume: 92, Issue:4A

    Topics: Abdomen; Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhi

2003
Niacin therapy in atherosclerosis.
    Current opinion in lipidology, 2004, Volume: 15, Issue:6

    Topics: Anti-Inflammatory Agents; Arteriosclerosis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hu

2004
The metabolic syndrome: modify root causes, treat risk factors.
    JAAPA : official journal of the American Academy of Physician Assistants, 2005, Volume: 18, Issue:3

    Topics: Coronary Disease; Diabetes Mellitus, Type 2; Education, Medical, Continuing; Humans; Hydroxymethylgl

2005
Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel.
    Current medical research and opinion, 2005, Volume: 21, Issue:5

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Europe; Humans; Hyperlipidemias; Hypolipidemic A

2005
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2005, Volume: 5, Issue:6

    Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diet; Drug T

2005
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
    Cardiovascular diabetology, 2006, Sep-26, Volume: 5

    Topics: Clofibric Acid; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxy

2006
Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease.
    Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:3

    Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Endothelium, Va

2007
Dyslipidaemia in diabetic patients: time for a rethink.
    Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:5

    Topics: Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Hu

2007
Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia.
    Current diabetes reviews, 2005, Volume: 1, Issue:2

    Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL;

2005
Combination therapy in the management of mixed dyslipidaemia.
    Journal of internal medicine, 2008, Volume: 263, Issue:4

    Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Routes; Dr

2008
Insulin action and substrate competition.
    Bailliere's clinical endocrinology and metabolism, 1993, Volume: 7, Issue:4

    Topics: Animals; Binding, Competitive; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Gluconeogenesi

1993
Interactions between glucose and FFA metabolism in man.
    Diabetes/metabolism reviews, 1996, Volume: 12, Issue:1

    Topics: Animals; Biological Transport; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; Human

1996
Triglyceride as a risk factor for coronary artery disease.
    The American journal of cardiology, 1998, Nov-05, Volume: 82, Issue:9A

    Topics: Biomarkers; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus,

1998
Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus.
    Diabetes care, 1992, Volume: 15, Issue:6

    Topics: Diabetes Mellitus, Type 2; Fatty Acids; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Models, B

1992
Hyperproinsulinemia and amyloid in NIDDM. Clues to etiology of islet beta-cell dysfunction?
    Diabetes, 1989, Volume: 38, Issue:11

    Topics: Amyloid; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Insulin; Insulin Resistance; Insulinoma;

1989

Trials

23 trials available for niacin and Diabetes Mellitus, Adult-Onset

ArticleYear
The efficacy of niacin supplementation in type 2 diabetes patients: Study protocol of a randomized controlled trial.
    Medicine, 2021, Mar-26, Volume: 100, Issue:12

    Topics: Adult; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dietary Supplements; Double-Blind Met

2021
Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose.
    International journal of clinical practice, 2013, Volume: 67, Issue:4

    Topics: Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Meth

2013
Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Arteriosclerosis, thrombosis, and vascular biology, 2014, Volume: 34, Issue:2

    Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Cross-O

2014
Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients.
    Atherosclerosis, 2015, Volume: 238, Issue:2

    Topics: Adult; Aged; Antioxidants; Biomarkers; Cholesterol, HDL; Cross-Sectional Studies; Diabetes Mellitus,

2015
Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.
    Vascular health and risk management, 2015, Volume: 11

    Topics: Aged; Biomarkers; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blin

2015
Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus.
    Arteriosclerosis, thrombosis, and vascular biology, 2015, Volume: 35, Issue:12

    Topics: Aged; Apolipoprotein B-100; Apolipoproteins A; Biomarkers; Cross-Over Studies; Delayed-Action Prepar

2015
Effect of niacin on triglyceride-rich lipoprotein apolipoprotein B-48 kinetics in statin-treated patients with type 2 diabetes.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:4

    Topics: Aged; Apolipoprotein B-48; Cardiovascular Diseases; Cross-Over Studies; Delayed-Action Preparations;

2016
Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes.
    Lipids in health and disease, 2016, Jul-12, Volume: 15, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Apolipoprotein B-100; Blood Glucose; Cholesterol, HDL; Cholesterol,

2016
Influence of the timing of low-dose aspirin on tolerability of prolonged-release nicotinic acid in patients at elevated cardiovascular risk.
    Current medical research and opinion, 2008, Volume: 24, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Dela

2008
Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy.
    Circulation, 2010, Jan-05, Volume: 121, Issue:1

    Topics: Aged; Animals; Cells, Cultured; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diabetic Ang

2010
Effect of niacin on preβ-1 high-density lipoprotein levels in diabetes.
    Metabolism: clinical and experimental, 2011, Volume: 60, Issue:2

    Topics: Aged; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Hig

2011
Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients.
    Diabetes & vascular disease research, 2010, Volume: 7, Issue:4

    Topics: Aged; Arterioles; Compliance; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combin

2010
Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome.
    Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:11

    Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Delayed-Action Preparations; Diabetes Mellit

2010
Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad.
    Minerva cardioangiologica, 2010, Volume: 58, Issue:5

    Topics: Aged; Aspirin; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Combinations; Dyslipidem

2010
Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.
    Metabolic syndrome and related disorders, 2012, Volume: 10, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Chy

2012
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
    Archives of internal medicine, 2002, Jul-22, Volume: 162, Issue:14

    Topics: Adult; Aged; Biomarkers; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol, HDL; Chole

2002
Effects of short-term experimental insulin resistance and family history of diabetes on pancreatic beta-cell function in nondiabetic individuals.
    The Journal of clinical endocrinology and metabolism, 2005, Volume: 90, Issue:10

    Topics: Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Tolerance Test

2005
Time-dependent effects of free fatty acids on glucose effectiveness in type 2 diabetes.
    Diabetes, 2006, Volume: 55, Issue:6

    Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Gluco

2006
Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients.
    Journal of cardiovascular risk, 1994, Volume: 1, Issue:3

    Topics: Adult; Aged; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug

1994
Effect of chromium nicotinic acid supplementation on selected cardiovascular disease risk factors.
    Biological trace element research, 1996, Volume: 55, Issue:3

    Topics: Administration, Oral; Adult; Aged; Blood Glucose; Cardiovascular Diseases; Cholesterol, HDL; Cholest

1996
Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control.
    The Annals of pharmacotherapy, 1997, Volume: 31, Issue:6

    Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 1; D

1997
The nicotinic acid analogue acipimox increases plasma leptin and decreases free fatty acids in type 2 diabetic patients.
    European journal of endocrinology, 2000, Volume: 143, Issue:3

    Topics: Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method;

2000
Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus.
    JAMA, 1990, Aug-08, Volume: 264, Issue:6

    Topics: Aged; Analysis of Variance; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical

1990

Other Studies

40 other studies available for niacin and Diabetes Mellitus, Adult-Onset

ArticleYear
A Fecal Metabolite Signature of Impaired Fasting Glucose: Results From Two Independent Population-Based Cohorts.
    Diabetes, 2023, Dec-01, Volume: 72, Issue:12

    Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Glucose; Humans; Niacin; Prediabetic State

2023
Dietary micronutrient adequacies and adherence to the Mediterranean diet in a population of older adults with type 2 diabetes: A cross-sectional study.
    Clinical nutrition ESPEN, 2023, Volume: 57

    Topics: Aged; Calcium; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diet, Mediterranean; Female; Huma

2023
[The effect of complex use of nicotinic acid electrophoresis and air bubble baths on microcirculation in patients with diabetic polyneuropathy].
    Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury, 2020, Volume: 97, Issue:3

    Topics: Balneology; Baths; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Electrophoresis; Humans; Microc

2020
Reducing CV risk in diabetes: An ADA update.
    The Journal of family practice, 2017, Volume: 66, Issue:5

    Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications;

2017
Targeted Microbiome Intervention by Microencapsulated Delayed-Release Niacin Beneficially Affects Insulin Sensitivity in Humans.
    Diabetes care, 2018, Volume: 41, Issue:3

    Topics: Adult; Case-Control Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Compoundin

2018
Hydroxytyrosol nicotinate, a new multifunctional hypolipidemic and hypoglycemic agent.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 99

    Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hy

2018
Sugar, sugar.
    International journal of clinical practice, 2013, Volume: 67, Issue:4

    Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucose Intolerance; Humans; Hypolipidemic Agents;

2013
The effect of pioglitazone and extended-release niacin on HDL-cholesterol in diabetes patients in a real-world setting.
    International journal of clinical practice, 2013, Volume: 67, Issue:11

    Topics: Analysis of Variance; Cholesterol, HDL; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug

2013
Discovery of an intravenous hepatoselective glucokinase activator for the treatment of inpatient hyperglycemia.
    Bioorganic & medicinal chemistry letters, 2013, Dec-15, Volume: 23, Issue:24

    Topics: Allosteric Regulation; Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Drug Evaluation, Preclin

2013
Involvement of the Niacin Receptor GPR109a in the LocalControl of Glucose Uptake in Small Intestine of Type 2Diabetic Mice.
    Nutrients, 2015, Sep-08, Volume: 7, Issue:9

    Topics: Animals; Blood Glucose; Caco-2 Cells; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Respon

2015
Management of the Metabolic Syndrome and the Obese Patient with Metabolic Disturbances: South Asian Perspective.
    Nestle Nutrition Institute workshop series, 2015, Volume: 82

    Topics: Adipose Tissue; Asia; Asian People; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Dietar

2015
Lipoprotein hydrophobic core lipids are partially extruded to surface in smaller HDL: "Herniated" HDL, a common feature in diabetes.
    Scientific reports, 2016, Jan-18, Volume: 6

    Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Fenofibra

2016
Effect of Combination Cholesterol-Lowering Therapy and Triglyceride-Lowering Therapy on Medical Costs in Patients With Type 2 Diabetes Mellitus.
    The American journal of cardiology, 2017, Feb-01, Volume: 119, Issue:3

    Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Cost-Benefit Analysis; Diabetes Mellitus,

2017
SIRT1 genetic variation and mortality in type 2 diabetes: interaction with smoking and dietary niacin.
    Free radical biology & medicine, 2009, Mar-15, Volume: 46, Issue:6

    Topics: Aged; Aging; Cohort Studies; Cytoprotection; Diabetes Mellitus, Type 2; Dietary Supplements; Female;

2009
The effect of body mass index on fasting blood glucose and development of diabetes mellitus after initiation of extended-release niacin.
    Metabolic syndrome and related disorders, 2010, Volume: 8, Issue:1

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Blood Glucose; Body Mass Index; Delayed-Action Pre

2010
Anti-diabetic effect of trigonelline and nicotinic acid, on KK-A(y) mice.
    Current medicinal chemistry, 2010, Volume: 17, Issue:20

    Topics: Alkaloids; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Glucokinase; Glucose-6-Phosph

2010
A structure-based approach for mapping adverse drug reactions to the perturbation of underlying biological pathways.
    PloS one, 2010, Aug-23, Volume: 5, Issue:8

    Topics: Breast Neoplasms; Computational Biology; Databases, Factual; Diabetes Mellitus, Type 2; Drug-Related

2010
B-vitamin consumption and the prevalence of diabetes and obesity among the US adults: population based ecological study.
    BMC public health, 2010, Dec-02, Volume: 10

    Topics: Adult; Age Distribution; Aged; Centers for Disease Control and Prevention, U.S.; Diabetes Mellitus,

2010
Association between extended-release niacin treatment and glycemic control in patients with type 2 diabetes mellitus: analysis of an administrative-claims database.
    Metabolism: clinical and experimental, 2011, Volume: 60, Issue:7

    Topics: Adult; Aged; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Drug Therapy, Combinatio

2011
Niacin results in reduced monocyte adhesion in patients with type 2 diabetes mellitus.
    Atherosclerosis, 2011, Volume: 215, Issue:1

    Topics: Adiponectin; Cardiovascular Diseases; Cell Adhesion; Cell Adhesion Molecules; Cholesterol, HDL; Diab

2011
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3

    Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as

2012
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3

    Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as

2012
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3

    Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as

2012
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3

    Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as

2012
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3

    Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as

2012
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3

    Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as

2012
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3

    Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as

2012
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3

    Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as

2012
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3

    Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as

2012
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3

    Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as

2012
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3

    Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as

2012
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3

    Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as

2012
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3

    Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as

2012
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3

    Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as

2012
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3

    Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as

2012
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3

    Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as

2012
Niacin seems OK for people with diabetes.
    Health news (Waltham, Mass.), 2002, Volume: 8, Issue:10

    Topics: Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Niacin

2002
The use of niacin in diabetes mellitus.
    Archives of internal medicine, 2003, Feb-10, Volume: 163, Issue:3

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypolipidemi

2003
Contribution of elevated free fatty acid levels to the lack of glucose effectiveness in type 2 diabetes.
    Diabetes, 2003, Volume: 52, Issue:11

    Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Emulsions; Fatty Acids, Nonesterified; Glucose

2003
[HDL cholesterol as protective factor. Deficiency threatens the diabetic heart].
    MMW Fortschritte der Medizin, 2003, Nov-27, Volume: 145, Issue:48

    Topics: Cholesterol, HDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypo

2003
The role of treatment to increase HDL-cholesterol and decrease triglyceride concentrations in prevention of coronary heart disease in Type 2 diabetes.
    Diabetic medicine : a journal of the British Diabetic Association, 2004, Volume: 21 Suppl 4

    Topics: Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hy

2004
[Lipid therapy in risk patients. Do we concentrate too much on LDL cholesterol?].
    MMW Fortschritte der Medizin, 2005, Apr-07, Volume: 147, Issue:14

    Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mell

2005
On the suppression of plasma nonesterified fatty acids by insulin during enhanced intravascular lipolysis in humans.
    American journal of physiology. Endocrinology and metabolism, 2005, Volume: 289, Issue:5

    Topics: Adult; Blood Glucose; Calorimetry, Indirect; Diabetes Mellitus, Type 2; Dose-Response Relationship,

2005
Transcriptome of the subcutaneous adipose tissue in response to oral supplementation of type 2 Leprdb obese diabetic mice with niacin-bound chromium.
    Physiological genomics, 2006, Nov-27, Volume: 27, Issue:3

    Topics: Adipose Tissue; Administration, Oral; Animals; Apoptosis Regulatory Proteins; Blood Glucose; Cholest

2006
Treating dyslipidaemia in the setting of diabetes mellitus and cardiovascular disease: another focus.
    International journal of clinical practice, 2006, Volume: 60, Issue:11

    Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA R

2006
Measure for measure--sugar or fats? Reconciling cardiovascular and diabetes risk with niacin therapy.
    Nature clinical practice. Endocrinology & metabolism, 2007, Volume: 3, Issue:2

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Lipoproteins; Metabolic Syndrome; Niacin

2007
Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients.
    Current medical research and opinion, 2007, Volume: 23, Issue:7

    Topics: Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Therapy, Combi

2007
Increased total and high-molecular weight adiponectin after extended-release niacin.
    Metabolism: clinical and experimental, 2008, Volume: 57, Issue:3

    Topics: Adiponectin; Adult; Body Composition; Body Weight; Cardiovascular Diseases; Delayed-Action Preparati

2008
Acute lowering of plasma fatty acids lowers basal insulin secretion in diabetic and nondiabetic subjects.
    Diabetes, 1998, Volume: 47, Issue:10

    Topics: 3-Hydroxybutyric Acid; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Emulsions; Fat Emulsions, Int

1998
Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes.
    Diabetes, 1999, Volume: 48, Issue:3

    Topics: 3-Hydroxybutyric Acid; Aged; C-Peptide; Diabetes Mellitus, Type 2; Fat Emulsions, Intravenous; Fatty

1999
Myocardial glucose utilization and optimization of (18)F-FDG PET imaging in patients with non-insulin-dependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2001, Volume: 42, Issue:12

    Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglucose F18; Glucose; Glucose

2001
Cholesterol and glycemic effects of Niaspan in patients with type 2 diabetes.
    Pharmacotherapy, 2001, Volume: 21, Issue:12

    Topics: Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Hypolipidemic Agents; Male; M

2001
Acute changes in plasma non-esterified fatty acid concentration do not change hepatic glucose production in people with type 2 diabetes.
    Diabetic medicine : a journal of the British Diabetic Association, 1990, Volume: 7, Issue:10

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glu

1990
Nicotinic acid in NIDDM.
    JAMA, 1990, Dec-19, Volume: 264, Issue:23

    Topics: Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Lipids; Niacin

1990
[Pellagra-like changes following glibenclamide treatment in a patient with diabetes mellitus and vitiligo].
    Dermatologische Monatschrift, 1988, Volume: 174, Issue:1

    Topics: Diabetes Mellitus, Type 2; Drug Eruptions; Female; Glyburide; Humans; Middle Aged; Pellagra; Vitilig

1988